FAZ from today: Interview with a German doctor: n
Post# of 154930
(Total Views: 433)
Posted On: 11/01/2021 11:21:54 AM
FAZ from today:
Interview with a German doctor: new guidelines, remdesivir is out!
"A new version of our Covid-19 guideline for inpatient treatment has been available since the beginning of the month. And there is new hope for the large gap in early-acting, antiviral drugs that could prevent a severe course. Previously recommended and effective is the monoclonal antibody therapy. But this is a therapy to be administered intravenously in the hospital; this is difficult for many patients in the first week of illness because they are not yet in the clinic and if the symptoms are mild at the beginning of the disease, they do not see any need to do so. Antibody therapy has shown success in studies, but in practice it is difficult to reach patients with it. We had placed a lot of hope in remdesivir, which should no longer be given according to the new guideline. Molnupiravir works similarly to remdesivir, but there is No published study yet, but a press release from the manufacturer.The advantage is that this Medi kament can be taken as a tablet. Therefore, a GP who diagnoses an infection and sees some risk may prescribe it. Molnupiravir could then be taken directly, and preliminary data suggests that it will cut hospital admissions in half. But in contrast to vaccination with this drug, there is reason to believe that the germ cells could be damaged - that is why the study participants were obliged to use contraception. So this will not be a miracle drug with no side effects, but a component in our therapy regime. It is not a substitute for vaccination, but it can make the disease less severe."...
Interview with a German doctor: new guidelines, remdesivir is out!
"A new version of our Covid-19 guideline for inpatient treatment has been available since the beginning of the month. And there is new hope for the large gap in early-acting, antiviral drugs that could prevent a severe course. Previously recommended and effective is the monoclonal antibody therapy. But this is a therapy to be administered intravenously in the hospital; this is difficult for many patients in the first week of illness because they are not yet in the clinic and if the symptoms are mild at the beginning of the disease, they do not see any need to do so. Antibody therapy has shown success in studies, but in practice it is difficult to reach patients with it. We had placed a lot of hope in remdesivir, which should no longer be given according to the new guideline. Molnupiravir works similarly to remdesivir, but there is No published study yet, but a press release from the manufacturer.The advantage is that this Medi kament can be taken as a tablet. Therefore, a GP who diagnoses an infection and sees some risk may prescribe it. Molnupiravir could then be taken directly, and preliminary data suggests that it will cut hospital admissions in half. But in contrast to vaccination with this drug, there is reason to believe that the germ cells could be damaged - that is why the study participants were obliged to use contraception. So this will not be a miracle drug with no side effects, but a component in our therapy regime. It is not a substitute for vaccination, but it can make the disease less severe."...
(1)
(0)